Article

Botulinum cosmetic injectors to cure blindness in Africa

Richard Weiss, MD, a Botox cosmetic injector, will bring physicians from all over the country for a fundraiser on November 16, 2007. The profits will be donated to curing blindness in Africa through the Eyes of Africa Initiative of the One World Sight Project. Despite the ease and affordability of the cataract treatment available to Africans, cataract is still responsible for almost half of the 7 million blind Africans.

Richard Weiss, MD, a botulinum (Botox, Allergan) cosmetic injector, will bring physicians from all over the country for a fundraiser on Nov. 16, 2007. The profits will be donated to curing blindness in Africa through the Eyes of Africa Initiative of the One World Sight Project. Despite the ease and affordability of the cataract treatment available to Africans, cataracts are still responsible for almost half of the 7 million blind Africans.

Due to the success of a pilot project in 2005, when 49 patients were treated in one day, which raised funds that cured 132 people of blindness in Tanzania and Tibet, the goal is to expand on this effort. Previously held only in southern California, this year's event will span the entire United States, with more than $175,000 already raised from more than 45 physicians around the country.

The makers of Botox (Allergen Medical, a division of Allergan Inc.) will once again donate the product and doctors will be donating their time.

Completion of the first comprehensive training center for community ophthalmology in Africa, to be located in Moshi, Tanzania, will be supported by the current Eyes of Africa initiative. There will also be a relief component with the training center, performing hundreds of live cataract surgeries simultaneous with the fundraising.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
© 2025 MJH Life Sciences

All rights reserved.